Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

被引：0
|
作者：
Brioli, Annamaria [1 ]
Pezzi, Annalisa [2 ]
Derudas, Daniele [3 ]
Petti, Maria Concetta [4 ]
Zannetti, Beatrice Anna [1 ]
Ferrara, Felicetto [5 ]
Rocchi, Serena [1 ]
Nobile, Francesco [6 ]
Baraldi, Anna [7 ]
Musto, Pellegrino [8 ]
Lanza, Francesco [9 ]
Mancuso, Katia [1 ]
Canepa, Letizia [10 ]
Catalano, Lucio [5 ]
Lazzaro, Antonio [11 ]
Pinotti, Graziella [12 ]
Boccadoro, Mario [13 ]
Cavo, Michele [1 ]
机构：
[1] Univ Bologna, Sch Med, Bologna, Italy
[2] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[3] GIMEMA Italian Myeloma Network, Cagliari, Italy
[4] GIMEMA Italian Myeloma Network, Rome, Italy
[5] GIMEMA Italian Myeloma Network, Naples, Italy
[6] GIMEMA Italian Myeloma Network, Reggio Di Calabria, Italy
[7] GIMEMA Italian Myeloma Network, Alessandria, Italy
[8] GIMEMA Italian Myeloma Network, Rionero In Vulture, Italy
[9] GIMEMA Italian Myeloma Network, Cremona, Italy
[10] GIMEMA Italian Myeloma Network, Genoa, Italy
[11] GIMEMA Italian Myeloma Network, Piacenza, Italy
[12] GIMEMA Italian Myeloma Network, Varese, Italy
[13] GIMEMA Italian Myeloma Network, Turin, Italy
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 13 条
  • [1] Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) as induction treatment for newly diagnosed Multiple Myeloma (MM) is associated with a lower rate of Second Primary Malignancies (SPMs) compared to Thalidomide-Dexamethasone (TD)
    Brioli, A.
    Pezzi, A.
    Muegge, L-O
    Derudas, D.
    Petti, M. C.
    Zannetti, B. A.
    Ferrara, F.
    Rocchi, S.
    Nobile, F.
    Baraldi, A.
    Musto, P.
    Lanza, F.
    Mancuso, K.
    Canepa, L.
    Catalano, L.
    Lazzaro, A.
    Pinotti, G.
    Boccadoro, M.
    Hochhaus, A.
    Cavo, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 69 - 69
  • [2] Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center
    Jimenez-Zepeda, Victor H.
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Culham, Marcia
    Luider, Joanne
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    [J]. BLOOD, 2015, 126 (23)
  • [3] Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHA-DEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients With Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN
    Sonneveld, Pieter
    Hacker, Emilie
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk M.
    [J]. BLOOD, 2011, 118 (21) : 290 - 290
  • [4] High-dose therapy/autologous stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD (Thalidomide/dexamethasone), VTD (bortezomib/thalidomide/dexamethasone) or VBMCP/VBAD plus bortezom
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Terol, M. J.
    de la Rubia, J.
    Palomera, L.
    de Arriba, F.
    Oriol, A.
    Alegre, A.
    Besalduch, J.
    de Paz, R.
    Garcia-Larana, J.
    Diaz-Mediavilla, J.
    Sureda, A.
    Lahuerta, J. J.
    Miguel, J. San
    Blade, J.
    [J]. BONE MARROW TRANSPLANTATION, 2009, 43 : S18 - S19
  • [5] Retrospective analysis of fractionated high-dose melphalan (F-MEL) and bortezomib-thalidomide-dexamethasone (VTD) with autotransplant (AT) support for advanced and refractory multiple myeloma (AR-MM).
    Pineda-Roman, Mauricio
    Fox, Michelle H.
    Hollmig, Klaus A.
    Anaissie, Elias J.
    van Rhee, Fritz
    Tricot, Guido
    Zangari, Maurizio
    Mohiuddin, Abid
    Barlogie, Bart
    [J]. BLOOD, 2006, 108 (11) : 884A - 884A
  • [6] Alternative Conditioning Regimens Incorporating Bortezomib (Bor) or Carmustine (car) with High-Dose Melphalan (HDM) are Safe and Effective for Multiple Myeloma Patients (pts) Receiving a Second Autologous Stem Cell Transplant (AutoSCT)
    Seddon, Amanda N.
    Laul, Anish
    Yadav, Udit
    Schultz, Kathryn
    Maciejewski, John
    Nathan, Sunita
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S132 - S132
  • [7] Rate of reduction in serum paraprotein in patients with IgG multiple myeloma comparing vamp like chemotherapy with high dose melphalan (HDM) as first line treatment.
    Sumpter, K
    Powles, R
    Horton, C
    Milan, S
    Treleaven, J
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 : S210 - S210
  • [8] HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
    Sonn-Eveld, Pieter
    Schmidt-Wolf, Ingo
    van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Salwender, Hans
    Zweegman, Sonja
    Vellenga, Edo
    Schubert, Joerg
    Blau, Igor Wolfgang
    Jie, Asiong
    Beverloo, Berna
    Hose, Dirk
    Jauch, Anna
    van de Velde, Helgi
    Schaafsma, Martijn
    Lindemann, Walter
    Kersten, Marie Jose
    Duehrsen, Ulrich
    Delforge, Michel
    Weisel, Katja
    Croockewit, Sandra
    Martin, Hans
    Wittebol, Shulamit
    Scheid, Christof
    Bos, Gerard
    van Marwijk-Kooy, Marinus
    Wijermans, Pierre
    Lokhorst, Henk
    Goldschmidt, Hartmut
    [J]. BLOOD, 2010, 116 (21) : 23 - 24
  • [9] First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
    Sonneveld, P.
    Eljarari, L.
    Salwender, H.
    Zweegman, S.
    Vellenga, E.
    Van der Holt, B.
    Schmidt-Wolf, I. G. H.
    Bertsch, U.
    Schubert, J.
    Blau, I. W.
    Jie, G. S. K.
    Beverloo, B.
    Jauch, A.
    Hose, D.
    Schaafsma, R.
    Kersten, M. J.
    Delforge, M.
    De Weerdt, O.
    Van der Griend, R.
    Wijermans, P. W.
    Martin, H.
    Van der Velde, H.
    Lokhorst, H. M.
    Goldschmidt, H.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S105 - S106
  • [10] First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
    Sonneveld, P.
    van der Holt, B.
    Schmidt-Wolf, I. G. H.
    Bertsch, U.
    el Jarari, L.
    Salwender, Hans-Juergen
    Zweegman, S.
    Vellenga, E.
    Schubert, J.
    Blau, I. W.
    Jie, G. S. K.
    Beverloo, B.
    Jauch, A.
    Hose, D.
    Schaafsma, R.
    Kersten, M. J.
    Delforge, M.
    de Weerdt, O.
    van der Griend, R.
    Wijermans, R. W.
    Martin, Hans
    van der Velde, H.
    Lokhorst, Henk M.
    Goldschmidt, H.
    [J]. BLOOD, 2008, 112 (11) : 243 - 244
12